Revision as of 23:22, 22 September 2019 by ClaireLewis (talk | contribs) (→‎References)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


  • Type: Uterotonic
  • Dosage Forms: Tablet, injection
  • Routes of Administration: IM, IV
  • Common Trade Names: Methergine

Adult Dosing

Postpartum hemorrhage

  • 0.2 mg IV q2-4h prn

Pediatric Dosing

  • Pediatric dosing not applicable or safety has not been established in pediatric patients.

Special Populations

Pregnancy Rating

  • Contraindicated during pregnancy
  • No known risk of teratogenicity
  • Risk of fetal hypoxia based on mechanism of action

Lactation risk

  • Avoid breastfeeding during treatment and 12 hours after discontinuing
  • Risk for infant vomiting, diarrhea, bradycardia, tachycardia, and seizures

Renal Dosing

  • Adult: Caution advised in impairment
  • Pediatric: N/A

Hepatic Dosing

  • Adult: Caution advised in impairment
  • Pediatric: N/A


  • Allergy to class/drug
  • Intra or periarterial administration
  • Pregnancy
  • Breastfeeding up to 12 hours after d/c
  • HTN
  • Toxemia

Adverse Reactions




  • Half-life: 3.4h
  • Metabolism: Liver
  • Excretion: Urine (<5% unchanged), feces

Mechanism of Action

  • Increases uterine contraction force and frequency


See Also